日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Ligand-activated EGFR/MAPK signaling but not PI3K, are key resistance mechanisms to EGFR-therapy in colorectal cancer.

配体激活的 EGFR/MAPK 信号通路(而非 PI3K)是结直肠癌中 EGFR 疗法产生耐药性的关键机制

Qu Xueping, Hamidi Habib, Johnson Radia M, Sokol Ethan S, Lin Eva, Eng Cathy, Kim Tae Won, Bendell Johanna, Sivakumar Smruthy, Kaplan Benjamin, de Sousa E Melo Felipe, Mancini Andrew, Wongchenko Matthew, Shi Yi, Shames David, Yan Yibing, Ciardiello Fortunato, Bais Carlos

First Results of Migoprotafib, a Potent and Highly Selective Src Homology-2 Domain-Containing Phosphatase 2 Inhibitor in Patients with Advanced Solid Tumors

Migoprotafib(一种强效且高选择性的含Src同源-2结构域的磷酸酶2抑制剂)在晚期实体瘤患者中的初步疗效

Johnson, Melissa L; Wolf, Beni B; Wang, Judy S; Philipovskiy, Alexander; Shapiro, Geoffrey I; Bockorny, Bruno; Guo, Wei; Shen, Jinshan; Jen, Kai Yu; LeRose, MaryBeth; Hunter, Tamieka Lauz; Padval, Mahesh; Schmidt-Kittler, Oleg; Bhatia, Namrata; Dubey, Sarita; Suchomel, Julia; Bendell, Johanna C; Jauhari, Shekeab; Eng-Wong, Jennifer; Lin, Jessica J

A phase 1 study of the CD40 agonist MEDI5083 in combination with durvalumab in patients with advanced solid tumors

CD40激动剂MEDI5083联合度伐利尤单抗治疗晚期实体瘤患者的I期研究

Tran, Ben; Voskoboynik, Mark; Bendell, Johanna; Gutierrez, Martin; Lemech, Charlotte; Day, Daphne; Frentzas, Sophia; Garrido-Laguna, Ignacio; Standifer, Nathan; Wang, Fujun; Ferte, Charles; Wang, Yue; Das, Mayukh; Carneiro, Benedito A

Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a/1b Nonrandomized Controlled Trial

抗TIGIT抗体Tiragolumab单药或联合Atezolizumab治疗晚期实体瘤患者:一项1a/1b期非随机对照试验

Kim, Tae Won; Bedard, Philippe L; LoRusso, Patricia; Gordon, Michael S; Bendell, Johanna; Oh, Do-Youn; Ahn, Myung-Ju; Garralda, Elena; D'Angelo, Sandra P; Desai, Jayesh; Hodi, F Stephen; Wainberg, Zev; Delord, Jean-Pierre; Cassier, Phillippe A; Cervantes, Andrés; Gil-Martin, Marta; Wu, Benjamin; Patil, Namrata S; Jin, Yanling; Hoang, Tien; Mendus, Diana; Wen, Xiaohui; Meng, Raymond; Cho, Byoung Chul

First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors

首次人体研究评估了强效、选择性抗CD73单克隆抗体oleclumab单独使用或与durvalumab联合使用治疗晚期实体瘤患者的疗效。

Bendell, Johanna; LoRusso, Patricia; Overman, Michael; Noonan, Anne M; Kim, Dong-Wan; Strickler, John H; Kim, Sang-We; Clarke, Stephen; George, Thomas J; Grimison, Peter S; Barve, Minal; Amin, Manik; Desai, Jayesh; Wise-Draper, Trisha; Eck, Steven; Jiang, Yu; Khan, Anis A; Wu, Yuling; Martin, Philip; Cooper, Zachary A; Elgeioushi, Nairouz; Mueller, Nancy; Kumar, Rakesh; Patel, Sandip Pravin

Predictive potential of angiopoietin-2 in a mCRC subpopulation treated with vanucizumab in the McCAVE trial

在McCAVE试验中,血管生成素-2在接受vanucizumab治疗的mCRC亚群中的预测潜力

Ferreira, Cláudia S; Babitzki, Galina; Klaman, Irina; Krieter, Oliver; Lechner, Katharina; Bendell, Johanna; Vega Harring, Suzana; Heil, Florian

Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial

Telaglenastat联合Cabozantinib或Everolimus治疗晚期或转移性肾细胞癌:一项开放标签I期试验

Meric-Bernstam, Funda; Tannir, Nizar M; Iliopoulos, Othon; Lee, Richard J; Telli, Melinda L; Fan, Alice C; DeMichele, Angela; Haas, Naomi B; Patel, Manish R; Harding, James J; Voss, Martin H; Owonikoko, Taofeek K; Carthon, Bradley; Srinivasan, Ramaprasad; Bendell, Johanna C; Jenkins, Yonchu; Whiting, Sam H; Orford, Keith; Bennett, Mark K; Bauer, Todd M

Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer

恩扎卢胺联合沙莫托利西布(LY3023414)或安慰剂治疗转移性去势抵抗性前列腺癌患者的Ib/II期研究

Sweeney, Christopher J; Percent, Ivor J; Babu, Sunil; Cultrera, Jennifer L; Mehlhaff, Bryan A; Goodman, Oscar B; Morris, David S; Schnadig, Ian D; Albany, Costantine; Shore, Neal D; Sieber, Paul R; Guba, Susan C; Zhang, Wei; Wacheck, Volker; Donoho, Gregory P; Szpurka, Anna M; Callies, Sophie; Lin, Boris Kin; Bendell, Johanna C

Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors

AZD4635(一种腺苷A2A受体拮抗剂)单药治疗或联合度伐利尤单抗治疗实体瘤患者的Ia/b期、开放标签、多中心研究

Lim, Emerson A; Bendell, Johanna C; Falchook, Gerald S; Bauer, Todd M; Drake, Charles G; Choe, Jennifer H; George, Daniel J; Karlix, Janet L; Ulahannan, Susanna; Sachsenmeier, Kris F; Russell, Deanna L; Moorthy, Ganesh; Sidders, Ben S; Pilling, Elizabeth A; Chen, Huifang; Hattersley, Maureen M; Das, Mayukh; Kumar, Rakesh; Pouliot, Gayle P; Patel, Manish R

Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial

Telaglenastat联合Everolimus治疗晚期肾细胞癌:一项随机、双盲、安慰剂对照的II期ENTRATA试验

Lee, Chung-Han; Motzer, Robert; Emamekhoo, Hamid; Matrana, Marc; Percent, Ivor; Hsieh, James J; Hussain, Arif; Vaishampayan, Ulka; Liu, Sandy; McCune, Steven; Patel, Vijay; Shaheen, Montaser; Bendell, Johanna; Fan, Alice C; Gartrell, Benjamin A; Goodman, Oscar B; Nikolinakos, Petros G; Kalebasty, Arash Rezazadeh; Zakharia, Yousef; Zhang, Zhentao; Parmar, Hema; Akella, Lalith; Orford, Keith; Tannir, Nizar M